Targeting Mitochondrial Dysfunction

For our lead product, Imeglimin, a New Drug Application was submitted in Japan by Sumitomo Dainippon Pharma in July 2020. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Presents New Results of Imeglimin Phase 2 and 3 Clinical Studies in Japan at the 64th Annual Meeting of the Japan Diabetes Society (JDS)

Kaku et al. Long-term efficacy and safety in Phase 3 study with Imeglimin as mono- and add-on therapy in Japanese T2DM patients: results from TIMES 2 trial Hata et al. Post hoc analysis of Phase 2 and 3 studies of…

Read this Press Release: Poxel Presents New Results of Imeglimin Phase 2 and 3 Clinical Studies in Japan at the 64th Annual Meeting of the Japan Diabetes Society (JDS)

Poxel Announces Participation at Upcoming Virtual Investor Conferences in June

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Announces Participation at Upcoming Virtual Investor Conferences in June

Poxel Announces Notice of its Annual General Meeting to be Held on June 23, 2021

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Announces Notice of its Annual General Meeting to be Held on June 23, 2021
Click here to show the previous slide Click here to show the next slide

Upcoming Events

JMP Securities Conference

Raymond James Human Health Innovations Conference

EASL ILC

Click here to show the previous slide Click here to show the next slide